High Tech Pharm Valuation

Q: What is the Fair Price of A106190 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

A106190 (₩13620) is trading below our estimate of [[fair value]] (₩16393.54)

Is A106190 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of A106190 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: A106190 (₩13620) is trading below our estimate of fair value (₩16393.54)

Significantly Below Fair Value: A106190 is trading below fair value, but not by a significant amount.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for A106190?

Other financial metrics that can be useful for relative valuation.

The above table shows the n/a ratio for A106190. This is calculated by dividing A106190's market cap by their current preferred multiple.
What is A106190's n/a Ratio?
n/a	0x
n/a	n/a
Market Cap	₩144.82b

A106190 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	1.8x
Enterprise Value/EBITDA	7.1x
PEG Ratio	n/a

Price to Earnings Ratio vs Peers

How does A106190's PE Ratio compare to its peers?

The above table shows the PE ratio for A106190 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	25.5x
A023910 Daihan PharmaceuticalLtd	5.1x	1.2%	₩151.7b
A032300 KOREA PHARMA	57.5x	n/a	₩172.3b
A214390 Kyongbo Pharmaceutical	33.2x	n/a	₩177.9b
A234080 JW Lifescience	6.4x	n/a	₩171.1b
A106190 High Tech Pharm	10.7x	n/a	₩144.8b

Price-To-Earnings vs Peers: A106190 is good value based on its Price-To-Earnings Ratio (10.7x) compared to the peer average (25.3x).

Price to Earnings Ratio vs Industry

How does A106190's PE Ratio compare vs other companies in the KR Pharmaceuticals Industry?

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	39.1%
	n/a	n/a	n/a

Fetching data

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	39.1%
	n/a	n/a	n/a

No more companies

Price-To-Earnings vs Industry: A106190 is good value based on its Price-To-Earnings Ratio (10.7x) compared to the KR Pharmaceuticals industry average (14.8x).

Price to Earnings Ratio vs Fair Ratio

What is A106190's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

A106190 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	10.7x
Fair PE Ratio	n/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate A106190's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.